UnknownPhase 3NCT04762758
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharnext S.C.A.
- Principal Investigator
- Sharam Attarian, MDCHU la Timone, Marseille , France
- Intervention
- (RS)-baclofen, naltrexone hydrochloride and D-sorbitol(drug)
- Enrollment
- 350 enrolled
- Eligibility
- 16-65 years · All sexes
- Timeline
- 2021 – 2024
Study locations (30)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, California, United States
- UC Davis Health Department of Physical Medicine and Rehabilitation, Sacramento, California, United States
- Hospital for Special Care, New Britain, Connecticut, United States
- University of Florida Clinical Research Center, Gainesville, Florida, United States
- University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States
- Advent Health Medical Group Neurology Orlando, Orlando, Florida, United States
- University of Kansas Medical Center Research Institute, Fairway, Kansas, United States
- Massachusetts General Hospital Neuromuscular Diagnostic Center, Boston, Massachusetts, United States
- University of Minnesota Health, Minneapolis, Minnesota, United States
- MU Health Care Neurology and Sleep Disorders Clinic, Columbia, Missouri, United States
- Hackensack Meridian Health Hackensack University Medical Center, Hackensack, New Jersey, United States
- Colombia University Department of Neurology, New York, New York, United States
- UNC Department of Neurology Peripheral Neuropathy Center, Chapel Hill, North Carolina, United States
- Atrium Health Neurosciences Institute, Charlotte, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Worldwide Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04762758 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07038239Genotype/Phenotype Correlation of MORC2 MutationsHospices Civils de Lyon
- RECRUITINGNCT06203093Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and BiobankingNew York Stem Cell Foundation Research Institute
- RECRUITINGNCT05902351Natural History Study for Charcot Marie Tooth DiseaseHereditary Neuropathy Foundation
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons →